Formal communication could help ease the transition of care from specialized myeloma centers to community clinic, according ...

The NCCN has added taletrectinib to its recommendations for use in all lines of treatments for non–small cell lung cancer ...

Adjuvant aspirin did not reduce recurrence or improve survival in patients with CRC liver metastases, phase 3 data showed at ...

Subcutaneous daratumumab makes it easier for patients to find appointments that fit with their lifestyles and schedules, ...

The frontline combination of ibrutinib with venetoclax was associated with complete response and durable remission for older patients with MCL.

Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane ...

Oncology nurses can help patients understand this novel mechanism of action and its potential as a treatment option.

The combination of relacorilant and nab-paclitaxel improved survival in platinum-resistant ovarian cancer following a break ...

Per ODAC and CHMP recommendations, subcutaneous daratumumab may become the first approved treatment for smoldering myeloma.

Panelists discuss how the treatment landscape for EGFR-mutant non–small cell lung cancer (NSCLC) has evolved to include 3 viable frontline options (osimertinib alone, osimertinib plus chemotherapy, ...